In February 22nd, the third people's Hospital of Shenzhen and Shenzhen national infectious disease clinical research center ( Hybio Pharmaceutical Co.Ltd(300199) ) signed a strategic cooperation agreement with the National Center for infectious diseases clinical research, and jointly established the collaborative innovation center and practice base for infectious diseases translational medicine, and set up an innovative system for clinical research on infectious diseases. To accelerate the clinical research and application of new drugs.
According to the agreement, the three parties jointly established the collaborative innovation center and practice base for infectious diseases translational medicine, breaking the inherent barrier between basic medicine and drug research and development, clinical and public health in the field of infectious diseases, and establishing direct correlation between them, from laboratory to hospital bed. Quickly transform the basic knowledge of clinical prevention and treatment into the new achievements of public health. The three parties will carry out comprehensive strategic cooperation in innovative project cooperation and development, scientific research project cooperation application, project transformation, industry university research academic exchange, compound talent exchange and training, so as to form a good situation of mutual promotion and common development of medical units and enterprises, and strive to realize the trend of "hospital enterprise cooperation, strong cooperation, win-win production and learning and serving the society".
At present, covid-19 virus variant is accelerating the spread, and the means of effective treatment and prevention are still limited. The research and development of covid-19 drugs has also become an urgent clinical need. The platform will rely on the respective advantages of the three parties, especially at the moment of severe covid-19 epidemic prevention and control, combined with the case related data of covid-19 patients admitted to Shenzhen Third People's Hospital, organize forces to tackle key technical problems at the first time, carry out clinical research of anti covid-19 virus projects, and accelerate the implementation of covid-19 drug research and development and clinical application and the promotion and application of products.
